“It’s a very positive development”
CEO Jens Bager is very pleased with the quarterly development in the Danish allergy drug group ALK-Abelló, pointing out that underlying growth is solid for the quarter.
BY BENJAMIN WERNER CHRISTENSEN
Things are on the right track for ALK-Abelló (ALK). That is the overall message to be deduced from CEO Jens Bager’s comments to the allergy drug group’s Q2 report, showing growth in revenue of 17% to DKK 615 million.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Here is ALK’s scientific focus
For abonnenter
ALK CEO expects favorable price
For abonnenter
ALK in house dust mite-drive in China
For abonnenter
